The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer

Status in 2016

Daniel S W Tan, Sue S. Yom, Ming S. Tsao, Harvey I. Pass, Karen Kelly, Nir Peled, Rex C. Yung, Ignacio I. Wistuba, Yasushi Yatabe, Michael Unger, Philip Mack, Murry W. Wynes, Tetsuya Mitsudomi, Walter Weder, David Yankelevitz, Roy S. Herbst, David R Gandara, David P. Carbone, Paul A. Bunn, Tony S K Mok & 1 others Fred R. Hirsch

Research output: Contribution to journalReview article

103 Citations (Scopus)

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.

Original languageEnglish (US)
Pages (from-to)946-963
Number of pages18
JournalJournal of Thoracic Oncology
Volume11
Issue number7
DOIs
StatePublished - 2016

Fingerprint

erbB-1 Genes
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
Protein-Tyrosine Kinases
Therapeutics
Guidelines
Neoplasm Metastasis
Biopsy
DNA
Brain
Research

Keywords

  • Brain metastases
  • EGFR mutation
  • Non-small cell lung cancer
  • Resistance
  • Therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer : Status in 2016. / Tan, Daniel S W; Yom, Sue S.; Tsao, Ming S.; Pass, Harvey I.; Kelly, Karen; Peled, Nir; Yung, Rex C.; Wistuba, Ignacio I.; Yatabe, Yasushi; Unger, Michael; Mack, Philip; Wynes, Murry W.; Mitsudomi, Tetsuya; Weder, Walter; Yankelevitz, David; Herbst, Roy S.; Gandara, David R; Carbone, David P.; Bunn, Paul A.; Mok, Tony S K; Hirsch, Fred R.

In: Journal of Thoracic Oncology, Vol. 11, No. 7, 2016, p. 946-963.

Research output: Contribution to journalReview article

Tan, DSW, Yom, SS, Tsao, MS, Pass, HI, Kelly, K, Peled, N, Yung, RC, Wistuba, II, Yatabe, Y, Unger, M, Mack, P, Wynes, MW, Mitsudomi, T, Weder, W, Yankelevitz, D, Herbst, RS, Gandara, DR, Carbone, DP, Bunn, PA, Mok, TSK & Hirsch, FR 2016, 'The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016', Journal of Thoracic Oncology, vol. 11, no. 7, pp. 946-963. https://doi.org/10.1016/j.jtho.2016.05.008
Tan, Daniel S W ; Yom, Sue S. ; Tsao, Ming S. ; Pass, Harvey I. ; Kelly, Karen ; Peled, Nir ; Yung, Rex C. ; Wistuba, Ignacio I. ; Yatabe, Yasushi ; Unger, Michael ; Mack, Philip ; Wynes, Murry W. ; Mitsudomi, Tetsuya ; Weder, Walter ; Yankelevitz, David ; Herbst, Roy S. ; Gandara, David R ; Carbone, David P. ; Bunn, Paul A. ; Mok, Tony S K ; Hirsch, Fred R. / The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer : Status in 2016. In: Journal of Thoracic Oncology. 2016 ; Vol. 11, No. 7. pp. 946-963.
@article{127cd2bfc04e42619bba61e608c5a5dc,
title = "The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016",
abstract = "Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent {"}actionable{"} alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.",
keywords = "Brain metastases, EGFR mutation, Non-small cell lung cancer, Resistance, Therapy, Tyrosine kinase inhibitor",
author = "Tan, {Daniel S W} and Yom, {Sue S.} and Tsao, {Ming S.} and Pass, {Harvey I.} and Karen Kelly and Nir Peled and Yung, {Rex C.} and Wistuba, {Ignacio I.} and Yasushi Yatabe and Michael Unger and Philip Mack and Wynes, {Murry W.} and Tetsuya Mitsudomi and Walter Weder and David Yankelevitz and Herbst, {Roy S.} and Gandara, {David R} and Carbone, {David P.} and Bunn, {Paul A.} and Mok, {Tony S K} and Hirsch, {Fred R.}",
year = "2016",
doi = "10.1016/j.jtho.2016.05.008",
language = "English (US)",
volume = "11",
pages = "946--963",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer

T2 - Status in 2016

AU - Tan, Daniel S W

AU - Yom, Sue S.

AU - Tsao, Ming S.

AU - Pass, Harvey I.

AU - Kelly, Karen

AU - Peled, Nir

AU - Yung, Rex C.

AU - Wistuba, Ignacio I.

AU - Yatabe, Yasushi

AU - Unger, Michael

AU - Mack, Philip

AU - Wynes, Murry W.

AU - Mitsudomi, Tetsuya

AU - Weder, Walter

AU - Yankelevitz, David

AU - Herbst, Roy S.

AU - Gandara, David R

AU - Carbone, David P.

AU - Bunn, Paul A.

AU - Mok, Tony S K

AU - Hirsch, Fred R.

PY - 2016

Y1 - 2016

N2 - Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.

AB - Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.

KW - Brain metastases

KW - EGFR mutation

KW - Non-small cell lung cancer

KW - Resistance

KW - Therapy

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84978264610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978264610&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.05.008

DO - 10.1016/j.jtho.2016.05.008

M3 - Review article

VL - 11

SP - 946

EP - 963

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -